Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature

被引:42
作者
Richard, J. -L. [1 ]
Almasri, M. [2 ]
Schuldiner, S. [1 ]
机构
[1] Univ Nimes Hosp, Med Ctr, Dept Diabetol & Nutr Dis, F-30240 Nimes, France
[2] Lapeyronie Univ Hosp, Dept Metab Dis, Montpellier, France
关键词
Bisphosphonates; Charcot neuro-osteoarthropathy; Diabetic foot; Diabetic neuropathy; Osteoprotegerin; RANK-L; Systematic review; RECEPTOR ACTIVATOR; NEUROARTHROPATHY; PAMIDRONATE; ARTHROPATHY; MECHANISM;
D O I
10.1007/s00125-012-2507-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim/hypothesis We undertook a systematic review of the literature concerning the efficacy and safety of bisphosphonates in acute Charcot neuropathic osteoarthropathy. Methods MEDLINE, PubMed, the Cochrane Database of Systematic Reviews, and abstracts presented during the meetings of the American Diabetes Association and the European Association of Diabetes were searched for relevant publications from the period January 1990 to September 2011. Results A total of ten studies on the treatment of acute Charcot osteoarthropathy with bisphosphonates were identified and included in the analysis. Only four clinical trials were published, three of which were randomised. Bisphosphonates appeared to induce significant reductions in skin temperature and bone turnover markers compared with placebo, without serious adverse events. Nevertheless, bisphosphonates did not shorten the immobilisation time. Moreover, no data were available regarding their long-term effects. Conclusions/interpretations Bisphosphonates have been shown to be effective for reducing bone turnover markers and skin temperature in some studies. Nevertheless, the long-term efficacy, specifically that regarding the occurrence of deformities and ulcerations, remains to be demonstrated as no follow-up studies have been published. Moreover, some studies have suggested that bisphosphonates may lengthen the resolution phase of the disease. In our opinion, the data are too weak to support the use of bisphosphonates as a routine treatment for acute Charcot neuroarthropathy.
引用
收藏
页码:1258 / 1264
页数:7
相关论文
共 37 条
  • [1] Anderson JJ, 2004, J FOOT ANKLE SURG, V43, P2285
  • [2] Intranasal calcitonin in the treatment of acute charcot neuroosteoarthropathy -: A randomized controlled trial
    Bem, Robert
    Jirkovska, Alexandra
    Fejfarova, Vladimira
    Skibova, Jelena
    Jude, Edward B.
    [J]. DIABETES CARE, 2006, 29 (06) : 1392 - 1394
  • [3] Bisphosphonates: Mechanism of action and role in clinical practice
    Drake, Mathew T.
    Clarke, Bart L.
    Khosla, Sundeep
    [J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (09) : 1032 - 1045
  • [4] Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO
  • [5] 2-E
  • [6] Audit of acute Charcot's disease in the UK: the CDUK study
    Game, F. L.
    Catlow, R.
    Jones, G. R.
    Edmonds, M. E.
    Jude, E. B.
    Rayman, G.
    Jeffcoate, W. J.
    [J]. DIABETOLOGIA, 2012, 55 (01) : 32 - 35
  • [7] Gough A, 1997, DIABETIC MED, V7, P527
  • [8] Guis S, 1999, J RHEUMATOL, V26, P1843
  • [9] Charcot neuro-osteoarthropathy
    Jeffcoate, William J.
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2008, 24 : S62 - S65
  • [10] The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes
    Jeffcoate, WJ
    Game, F
    Cavanagh, PR
    [J]. LANCET, 2005, 366 (9502) : 2058 - 2061